Republic of Korea-based biosimilar developer Celltrion, maker of Inflectra, has announced that it will launch a contract development and manufacturing business to develop novel agents alongside its biosimilar pipeline.
Republic of Korea-based biosimilar developer Celltrion, maker of Inflectra, has announced that it will launch a contract development and manufacturing business to develop novel agents alongside its biosimilar pipeline.
Celltrion said in a statement that the new undertaking will allow the company to collaborate and partner with research institutes and biotechnology firms to successfully commercialize innovative molecules, and partners would benefit from sharing in Celltrion’s accumulated development expertise.
The new effort will focus initially on the therapeutic areas that have “the greatest synergy with Celltrion’s portfolio,” namely inflammatory diseases, cancer, and cardiovascular disease.
The news follows closely on the heels of another announcement concerning partnerships for Celltrion; on May 30, 2018, the company signed an agreement with Yonsei University Health System (which includes 4 hospitals that serve 3 million outpatients and 1 million inpatients each year) to jointly develop and license fc-saxatilin, a proposed therapy for the treatment of ischemic stroke.
Saxatilin is a snake venom that exerts thrombolytic and antiplatelet effects by interacting with multiple integrins on platelets. The researchers developing the drug believe that fc-saxatilin, an Fc-fusion protein, could prevent vascular leakage in patients with ischemic stroke by regulating occludin expression in endothelial tight junctions.1
Celltrion expects that the market for drugs targeting ischemic stroke will grow by 6.8% per year until 2020, and it hopes that an eventually approved fc-saxatilin could compete with Genentech’s thrombolytic drug, alteplase (Activase), for a share of the market.
A Celltrion executive said in a statement, “In order to bolster our next-generation pipeline, in addition to the development of antibody biosimilars, we have continued efforts to explore platform technologies and new molecules in relation to the development of new biopharmaceuticals and synthetic drugs. Through the agreement with Yonsei University Health System, we will push for open innovation to secure new drug pipelines.”
Reference
1. Choi HJ, Kwon I, Kim NE, et al. Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression. Thromb Haemost. 2017;117(03): 595-605. doi: 10.1160/TH16-06-0469.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.